|
|
Article: Competitive Edge: New Law Requires Pharmaceutical Companies to Notify Agreements With the U.S. Antitrust Regulators.
- Article from:
- Mondaq Business Briefing
- Article date:
- February 25, 2004
- Author:
CopyrightCOPYRIGHT 2004 Mondaq Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
By Joel R. Grosberg and Nicholas R. Koberstei
The U.S. Federal Trade Commission (FTC) published a notice that, effective January 7, 2004, pharmaceutical companies must now file certain agreements with the FTC and the U.S. Department of Justice (DOJ) within 10 business days of the execution of the agreement. This new law, which is part of Title XI of the Medicare Prescription Drug, Improvement and Modernization Act of 2003, establishes a new mandatory notification process for certain agreements between brand-name and generic pharmaceutical companies active in the U.S.
The new law requires pharmaceutical companies to file two categories of agreements with ...